Clozapine inhibits synaptic transmission at GABAergic synapses established by ventral tegmental area neurones in culture

Neuropharmacology

Volumn 39, Issue 9, 2000, Pages 1536-1543

  Michel, F J ^a   Trudeau, L E ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Atypical antipsychotics; Clozapine; GABA(A) receptors; Midbrain; Schizophrenia

Indexed keywords

3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; CLOZAPINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GABAERGIC SYSTEM; IN VITRO STUDY; INHIBITORY POSTSYNAPTIC POTENTIAL; NERVE CELL CULTURE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION; VENTRAL TEGMENTUM;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GABA ANTAGONISTS; MEMBRANE POTENTIALS; NEURONS; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; SYNAPSES; SYNAPTIC TRANSMISSION; VENTRAL TEGMENTAL AREA;

EID: 0034077277     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00239-7     Document Type: Article

References (36)

1. Altamura A.C., De Novellis F., Mauri M.C., Gomeni R. Plasma and brain pharmacokinetics of mianserin after single and multiple dosing in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 11:1987;23-33.
2. Andersson C., Chakos M., Mailman R., Lieberman J. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. The Psychiatric Clinics of North America. 21:1998;151-179.
3. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. The Journal of Pharmacology and Experimental Theraputics. 283:1997;226-234.
4. Bacopoulos N.C., Spokes E.G., Bird E.D., Roth R.H. Antipsychotic drug action in schizophrenic patients: effect on cortical dopamine metabolism after long-term treatment. Science. 205:1979;1405-1407.
5. Baldessarini R.J., Centorrino F., Flood J.G., Volpicelli S.A., Huston-Lyons D., Cohen B.M. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 9:1993;117-124.
6. Bekkers J.M., Stevens C.F. Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture. Proceedings of the National Academy of Science, USA. 88:1991;7834-7838.
7. A receptors suggest differential targeting of receptor subtypes. Journal of Neuroscience. 19:1999;2960-2973.
8. Brunello N., Masotto C., Steardo L., Markstein R., Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology. 13:1995;177-213.
9. Canton H., Verriele L., Colpaert F.C. Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites. Europan Journal of Pharmacology. 191:1990;93-96.
10. Cardozo D.L. Midbrain dopaminergic neurons from postnatal rat in long-term primary culture. Neuroscience. 56:1993;409-421.
11. Coward D.M. General pharmacology of clozapine. British Journal of Psychiatry Supplement. 17:1992;5-11.
12. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry. 148:1991;1474-1486.
13. George B., Kulkarni S.K. Protective effect of clozapine against pentylenetetrazol convulsions and kindling. Methods and Findings in Experimental and Clinical Pharmacology. 20:1998;395-401.
14. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 41:1991;1-24.
15. Hand T.H., Hu X.T., Wang R.Y. Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Research. 415:1987;257-269.
16. Hyde T.M., Weinberger D.R. Seizures and schizophrenia. Schizophrenia Bulletin. 23:1997;611-622.
17. A receptor blockade in the anterior ventral tegmental area increases extracellular levels of dopamine in the nucleus accumbens of rats. Journal of Neurochemistry. 69:1997;137-143.
18. Johnson S.W., North R.A. Two types of neurone in the rat ventral tegmental area and their synaptic inputs. Journal of Physiology (London). 450:1992;455-468.
19. Joyce J.N. The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology (Berlin). 112:1993;S16-S34.
20. Kornhuber J., Schultz A., Wiltfang J., Meineke I., Gleiter C.H., Zochling R., Boissl K.W., Leblhuber F., Riederer P. Persistence of haloperidol in human brain tissue. American Journal of Psychiatry. 156:1999;885-890.
21. Korpi E.R., Wong G., Luddens H. Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine. Naunyn-Schmiedeberg's Archives of Pharmacology. 352:1995;365-373.
22. Minabe Y., Watanabe K., Nishimura T., Ashby C.R.J. Acute and chronic administration of clozapine produces greater proconvulsant actions than haloperidol on focal hippocampal seizures in freely moving rats. Synapse. 29:1998;272-278.
23. Olesen O.V. Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations. Clinical Pharmacokinetics. 34:1998;497-502.
24. Ossowska K., Pietraszek M., Wardas J., Nowak G., Wolfarth S. Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. 359:1999;280-287.
25. Pacia S.V., Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology. 44:1994;2247-2249.
26. Reynolds G.P. Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature. 305:1983;527-529.
27. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 7:1992;261-284.
28. Snyder S.H., Greenberg D., Yamumura H.I. Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects. Journal of Psychiatric Research. 11:1974;91-95.
29. Squires R.F., Saederup E. A review of evidence for GABAergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis. Neurochemical Research. 16:1991;1099-1111.
30. A receptors. Neurochemical Research. 22:1997;151-162.
31. A receptors. Neurochemical Research. 23:1998;1283-1290.
32. Steffensen S.C., Svingos A.L., Pickel V.M., Henriksen S.J. Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. Journal of Neuroscience. 18:1998;8003-8015.
33. Stevens J.R., Denney D., Szot P. Sensitization with clozapine: beyond the dopamine hypothesis. Biological Psychiatry. 42:1997;771-780.
34. Van Tol H.H., Bunzow J.R., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
35. Weigmann H., Hartter S., Fischer V., Dahmen N., Hiemke C. Distribution of clozapine and desmethylclozapine between blood and brain in rats. European Neuropsychopharmacology. 9:1999;253-256.
36. A receptors. European Journal of Pharmacology. 314:1996;319-323.